BioSpace News Archive

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the release of its two-part white paper, “Accurately Diagnosing Alzheimer’s Disease: Shortcomings of Blood Biomarkers and Need for Definitive, Non-invasive Diagnostic Testing.”

AB Science S.A. provides an update on the schedule for the evaluation by the Committee for Medicinal Products for Human Use of the European Medicines Agency and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis.

GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to announce that it has completed its contractual obligations relating to the first stage of the binding Letter of Intent (“LOI”)

Merck, known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year-from No. 67 overall in 2022 to No. 29 overall in 2023.

C2N Diagnostics announced the presentation of two research studies at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders that bolster the role of the Precivity-related blood biomarkers (BBM) to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors or the Compensation Committee thereof, as applicable, approved the grant of non-qualified stock options to purchase an aggregate of 350,000 shares of the Company’s common stock to two new employees on March 30 and April 3, 2023, respectively.

Celyad Oncology received a letter on March 31, 2023 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450 for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million.

Codexis, Inc., a leading enzyme engineering company, announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors.

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023 at 4:30 PM Eastern Time.